What Growth Drivers Underpin the Stelara Ustekinumab Market? The rise in prevalence of psoriasis patients is a significant propellant for the growth of the Stelara ustekinumab market. Psoriasis ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Stelara was first approved for psoriasis 10 years ago, and follow-up indications in psoriatic arthritis and Crohn’s disease have kept the drug growing at a healthy pace to reach more than $5 ...

Johnson & Johnson ( JNJ, Financial) stock saw a 2% decline on Wednesday following a robust fourth-quarter earnings report that surpassed Wall Street expectations. The healthcare giant, recently ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, according to a poster presented at Maui Derm Hawaii 2025. AX-158 has ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...